Gopal Subramanium | |
---|---|
Former Solicitor General | |
In office June 2009 – June 2011 |
|
Preceded by | Goolam Essaji Vahanvati |
Succeeded by | Rohinton Fali Nariman |
Personal details | |
Born | 1957/1958 (age 58–59) |
Citizenship | Indian |
Nationality | Indian |
Children | Gauri Giriraj |
Alma mater | Delhi University |
Occupation | Lawyer |
Gopal Subramanium (born c. 1958), is an Indian lawyer and Senior Advocate who practices primarily in the Supreme Court of India and the Delhi High Court. He also served as the Solicitor General of India from 2009-2011.
Gopal Subramanium commenced his career with Shardul S. Shroff, who established Amarchand & Mangaldas & Suresh A Shroff & Co in Delhi in 1980. He appeared as counsel for the states of Madhya Pradesh and Uttar Pradesh, often traveling to these states for hearings. He then worked under D. P. Wadhwa, who rose to become a judge of the Supreme Court and later under Soli Sorabjee, former Attorney General. In 1993, Mr. Subramanium was designated a Senior Advocate (the equivalent of a Queen's Counsel in the UK) suo motu by the Supreme Court, one of the youngest to be so designated in the Supreme Court's history. His varied work-experience includes:
Between 2005 and 2009 he held the office of Additional a Solicitor General of India, and subsequently served as the Solicitor General of India from 2009-2011. During his tenure as Solicitor General, he also served as the Chairman of the Bar Council of India. As a senior law officer to the Government of India, Mr. Subramanium represented the Government, as lead counsel, in a wide range of matters involving complex questions of constitutional and criminal law such as :
Subramanium also represented the government in cases like OBC quota in central educational institutions, sealing of commercial buildings in residential areas of Delhi.
He has assisted the Supreme Court as Amicus curaie in many cases including Sohrabuddin Sheikh fake encounter case. Along with T. R. Andhyarujina, he represented Novartis in the case Novartis v. Union of India & Others concerning evergreening of patents, a case which Novartis India managing director Ranjit Shahani described as "a setback for patients that will hinder medical progress for diseases without effective treatment options."